Bronchial carcinoid tumors are an uncommon group of lung tumors. The first report of BCT was by Laennac in 1831. They represent about 1% of all primary lung tumors and about 80% are centrally located, within the lobar and segmental bronchi. 1,2 BCTs were initially classified as benign tumors but now more appropriately classified as malignant tumors. They arise from the kulchitsky cells in the bronchial mucosa, more often in the cartilaginous portion of the tracheobronchial tree, covered by intact epithelium. They are highly vascular and may have a broad based or polypoid attachment. BCTs are capable of secreting biologically active substances. Over 80% of the tumors express somatostatin receptor subtype 2. The cause of BCTs is not proven and there is no strong association with smoking and environmental carcinogens. Familial BCTs have been reported with or without multiple endocrine neoplasia type 1. Leothela et al., 3 attributed BCTs to loss of heterogeneity in multiple chromosomes. The World Health Organization classifies BCTs into 2 groups. Typical BCTs are well differentiated with very low malignant potential, have less than 2 mitotic figures per 10high power field and no evidence of necrosis. Atypical BCT have more than 2-10 mitotic figures per 10 high power field and evidence of necrosis. Typical BCTs are about four times more common than atypical BCTs. We are reporting a case of typical bronchial carcinoid tumor since none has been reported before in the sub-region, to the best of our knowledge.